| 郭彦君,周纯武,史仲华,刘德忠,李槐,李忱瑞,曾辉英,姜文浩.肝动脉化疗栓塞治疗鼻咽癌肝转移疗效观察[J].中国医学影像技术,2005,21(5):738~741 |
| 肝动脉化疗栓塞治疗鼻咽癌肝转移疗效观察 |
| Clinical efficacy of hepatic arterial chemoembolization for liver metastases in patients with nasopharyngeal carcinoma |
| 投稿时间：2004-10-02 修订日期：2005-01-11 |
| DOI： |
| 中文关键词: 鼻咽癌 肝转移 化学栓塞,治疗性 |
| 英文关键词:Nasopharyngeal neoplasms Liver metastases Chemoembolization, therapeutic |
| 基金项目: |
|
| 摘要点击次数: 2651 |
| 全文下载次数: 1183 |
| 中文摘要: |
| 目的 探讨肝动脉化疗栓塞在鼻咽癌肝转移治疗中的应用及其价值。方法 对35例鼻咽癌肝转移患者进行了肝动脉化疗栓塞治疗,其中32例可评价病例均进行了肝动脉化疗/栓塞,按肿瘤位置及供血情况相应分配化疗药物用量。肝转移瘤经化疗栓塞治疗的疗效及生存期情况采用SPSS软件进行统计分析。结果 肝转移瘤经化疗栓塞后总的临床有效率(完全缓解5例 + 部分缓解10例)为46.9%(15/32)。单纯行肝动脉灌注化疗与同时行灌注化疗并联合栓塞治疗患者的临床疗效无统计学差异。全部患者的平均生存期为12.66个月,其1、2、3年累积生存率分别为43.8%、15.6%及6.3%。无严重的并发症。结论 肝动脉化疗栓塞可以作为治疗鼻咽癌肝转移瘤的一种姑息手段。 |
| 英文摘要: |
| Objective To evaluate the clinical efficacy of hepatic arterial chemoembolization for liver metastases in patients with nasopharyngeal carcinoma. Methods From September 1989 to January 2002, 35 patients with liver metastases from nasopharyngeal carcinoma were treated with hepatic arterial chemoembolization. Thirty-two patients were evaluable, 3 lost to follow-up. The hepatic arterial chemoembolization was used in all patients. The catheter was introduced via femoral artery on one side (usually on the right side), and the combined antineoplastic agents and / or embolic materials were infused into the selected arterial branches supplying the hepatic tumors. For patients with recurrent nasopharyngeal carcinoma and/or with no Objective responses, the radiation therapy and/or systematic chemotherapy were referred to. The difference in the treatment efficacy was evaluated with χ2 method. The survival was computed by Kaplan-Meier method and compared with the log-rank test. Results With a mean duration of follow-up of 13 months (1-59 months), the overall response rate was 46.9% (15/32), with a 15.6% complete response rate and a 31.3% partial response rate. There was no difference in treatment efficacy between those who received hepatic arterial infusion chemotherapy only and those who received both hepatic arterial chemotherapy and embolization. The overall mean survival duration was 12.66 months (median 9 months). The 1, 2, 3-year survival rates were 43.8%, 15.6%, and 6.3% respectively. The prolonged survival was observed in the responders (with a median survival time of 15 months, vs 5 months for nonresponders), and the difference was significant. The most frequently observed adverse effects were fever, nausea / vomiting, and abdominal pain, etc. No severe complications were observed. Conclusion Hepatic arterial chemoembolization is a feasible procedure with acceptable side effects, which could be used as a palliative treatment in patients with liver metastases from nasopharyngeal carcinoma. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
